Clinical trials: GITR
Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies
Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors
TRX518-001 is an open label, non-randomized single group assignment, Phase 1 single dose escalation study in adults with biopsy proven unresectable Stage III or Stage IV melanoma or other solid tumor malignancies.
- Trial name
- TRX518-001 (NCT01239134)
- Testing
- TRX518
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Leap Therapeutics, Inc.
Rheumatoid Arthritis
Glucocorticoid-induced Tumour Necrosis Factor Receptor Related Protein (GITR) in Rheumatoid Arthritis
This study aimed to measure serum and synovial fluid (SF) levels of GITR in patients with recent onset RA before and after initiation of therapy
- Trial name
- GITR (NCT03763201)
- Testing
- measurement of GITR
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Benha University
Glioblastoma
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
This is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and stereotactic radiosurgery (SRS) for recurrent Glioblastoma (GBM).
- Trial name
- NCT04225039
- Testing
- INCMGA00012, INCAGN01876, SRS
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pennsylvania
Cancer of the Head and Neck
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
This is a phase Ib study with a safety lead-in (n = 6 per arm) evaluating combinatorial DPV-001 + sequenced PD-1 blockade, with or without GITR agonist, in recurrent or metastatic HNSCC.
- Trial name
- NCT04470024
- Testing
- INCAGN01876, INCMGA00012, DPV-001
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Providence Health & Services
Advanced Solid Tumors
A Study of ASP1951 in Subjects With Advanced Solid Tumors
The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or…
- Trial name
- NCT03799003
- Testing
- ASP1951, pembrolizumab
- Where
- 32 sites in United States, Canada and 2 more
- Volunteers
- 119 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Squamous Cell Carcinoma of Head and Neck
Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
There are two main goals of this study: The first is to find the highest safe dose of REGN6569 when given with cemiplimab. The second is to get some initial information about how well the REGN6569 in combination with cemiplimab…
- Trial name
- NCT04465487
- Testing
- REGN6569, Cemiplimab
- Where
- 10 sites in United States, Spain
- Volunteers
- 38 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumors, Lymphomas
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
The purpose of this trial is to explore the clinical utility of two investigational antibodies in patients with advanced cancer or lymphomas. This is a multi-center, open-label Phase I/Ib study.
- Trial name
- NCT02740270
- Testing
- GWN323, PDR001
- Where
- 9 sites in United States, Canada and 4 more
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Metastatic Melanoma
Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma
Our proposed study is designed to test the safety of a new vaccine against melanoma. The induction of immune activity against cancers such as melanoma is a promising approach to cancer treatment, but to date, only a few…
- Trial name
- NCT01216436
- Testing
- Vaccination with RNA-transfected mature autologous DC
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Duke University
Advanced Solid Tumors
A Study in Adult Subjects With Select Advanced Solid Tumors
To evaluate the safety and tolerability of MEDI1873 in adult subjects with selected advanced solid tumors.
- Trial name
- NCT02583165
- Testing
- MEDI1873
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- MedImmune LLC
Advanced Malignancies, Metastatic Cancer
A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
This was an open-label, non-randomized Phase 1/2 safety study of INCAGN01876 in participants with advanced or metastatic solid tumors that was conducted in 2 parts.
- Trial name
- NCT02697591
- Testing
- INCAGN01876
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Incyte Biosciences International Sàrl
GITR, GITR Ligand
Immune Indicators of Uveitis
This study will try to identify markers of immune activity in uveitis patients that correlate with the state of disease activity. Uveitis is a group of inflammatory eye diseases that can cause vision loss.
- Conditions
- GITR, GITR Ligand, Uveitis, Immunosuppression
- Trial name
- NCT00089739
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Eye Institute (NEI)